Magnetic Bio-Metal–Organic Framework Nanocomposites Decorated With Folic Acid Conjugated Chitosan As a Promising Biocompatible Targeted Theranostic System for Cancer Treatment Publisher Pubmed



Nejadshafiee V^{1, 2} ; Naeimi H² ; Goliaei B³ ; Bigdeli B³ ; Sadighi A⁴ ; Dehghani S¹ ; Lotfabadi A⁵ ; Hosseini M¹ ; Nezamtaheri MS³ ; Amanlou M⁶ ; Sharifzadeh M⁷ ; Khoobi M^{1, 8}
Source: Materials Science and Engineering C Published:2019

Abstract

In this work, a multifunctional magnetic Bio-Metal-Organic Framework (Fe 3 O 4 @Bio-MOF) coated with folic acid-chitosan conjugate (FC) was successfully prepared for tumor-targeted delivery of curcumin (CUR) and 5-fluorouracil (5-FU) simultaneously. Bio-MOF nanocomposite based on CUR as organic linker and zinc as metal ion was prepared by hydrothermal method in the presence of amine-functionalized Fe 3 O 4 magnetic nanoparticles (Fe 3 O 4 @NH 2 MNPs). 5-FU was loaded in the magnetic Bio-MOF and the obtained nanocarrier was then coated with FC network. The prepared nanocomposite (NC) was fully characterized by high resolution-transmission electron microscope (HR-TEM), field emission scanning electron microscopy (FE-SEM), Dynamic light scattering (DLS), X-ray diffraction analysis (XRD), thermogravimetric analysis (TGA), vibrating sample magnetometry (VSM), nuclear magnetic resonance (NMR), and UV–vis analyses. In vitro release study showed controlled release of CUR and 5-FU in acidic pH confirming high selectivity and performance of the carrier in cancerous microenvironments. The selective uptake of 5-FU-loaded Fe 3 O 4 @Bio-MOF-FC by folate receptor-positive MDA-MB-231 cells was investigated and verified. The ultimate nanocarrier exhibited no significant toxicity, while drug loaded nanocarrier showed selective and higher toxicity against the cancerous cells than normal cells. SDS PAGE was also utilized to determine the protein pattern attached on the surface of the nanocarriers. In vitro and in vivo MRI studies showed negative signal enhancement in tumor confirming the ability of the nanocarrier to be applied as diagnostic agent. Owing to the selective anticancer release and cellular uptake, acceptable blood compatibility as well as suitable T 2 MRI contrast performance, the target nanocarrier could be considered as favorable theranostic in breast cancer. © 2019 Elsevier B.V.